Dew, why BLA filing is delayed until July/August? My understanding is that nonclinical and CMC modules must have been complete by now. The only missing part is clinical and in clinical only everything is available except that 90-day antibody results.
GTCB is behaving more like a big pharma than like a small pharma when it comes to timings.
Moreover for clinical, hardly 32 patients are in the study. Summarizing 32 patients data is not same as thousands of patients. With huge cash burn rate, shouldn't his management hurry up with these things?
Best Regards,
Market Data 
Markets 
AI
